C Ray Therapeutics Leverages China-Based IIT Model to Speed Radiopharmaceutical Development

C Ray Therapeutics is drawing attention to China’s Investigator-Initiated Trial framework as a way to speed development of next-generation radiopharmaceuticals. In a recent LinkedIn update, the company linked rising interest in IITs to discussions at the JPM Healthcare Conference and an FDA cell and gene therapy roundtable, where dual-track clinical approaches were highlighted.

The company argues IITs help address high translational uncertainty between animal and human biodistribution, as well as complex dose selection in radioligand therapies. C Ray Therapeutics also notes that investors and partners increasingly seek early human biodistribution and dosimetry data as de-risking signals before committing to large, expensive clinical programs.

According to the post, C Ray Therapeutics has already applied the China-based IIT model across more than 10 clinical sites, enrolling over 150 subjects. The company reports timelines of six to nine months from formulation to first-in-human studies, which could indicate a capital-efficient route to early clinical validation if these metrics prove sustainable and align with regulatory expectations.

The firm is also increasing its industry visibility, with Senior Director of Business Development Andrew Li scheduled to speak at the TRP Target Selection & Drug Design Summit in Boston. He is expected to discuss using IIT structures to ease Phase Zero and first-in-human hurdles, positioning the company as an early mover in IIT-enabled radiopharmaceutical development.

Taken together, these developments suggest C Ray Therapeutics is focusing on operational and clinical execution advantages rather than headline product announcements. If its IIT-based approach continues to deliver faster, data-rich early trials, it may strengthen the company’s appeal as a development partner within the global radiopharmaceutical ecosystem.